Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant

Prior COVID-19 infection reduces infection risk for up to 10 months
3 June 2021
Lessons from the last pandemic point the way toward universal flu vaccines
4 June 2021

Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant

Levels of antibodies in the blood of vaccinated people that are able to recognise and fight the new SARS-CoV-2 Delta variant first discovered in India (B.1.617.2) are on average lower than those against previously circulating variants in the UK, according to new laboratory data from the Francis Crick Institute and the National Institute for Health Research (NIHR) UCLH Biomedical Research Centre, published today (Thursday) as a Research letter in The Lancet.

Comments are closed.